Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience Inc (DARE)
NASDAQ:DARE
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.53Last Year’s EPS
-0.84Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: 1.73%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlights Daré Bioscience's strategic progress and innovative approaches to advancing their women's health portfolio, with significant developments in Sildenafil Cream and Ovaprene. However, financial challenges and delays in the Ovaprene study pose noteworthy concerns.Company Guidance
During the call, Daré Bioscience provided guidance on their strategic plan to make their proprietary Sildenafil Cream formulation available by prescription as a compounded drug under Section 503B of the FDCA. The company targets the fourth quarter of 2025 for this launch through a 503B-registered outsourcing facility partner. This approach aims to accelerate the availability of the product while pursuing FDA approval. Daré anticipates recording revenue from this initiative starting in the fourth quarter of 2025. The company expects to invest less than $1 million to support activities required for this pathway. Additionally, Daré highlighted their broader business strategy, which includes advancing clinical development, pursuing strategic collaborations, exploring portfolio expansion opportunities, and seeking non-dilutive funding sources, with up to $20.7 million in such funding announced for 2024.Sildenafil Cream Formulation Announcement
Daré Bioscience plans to make its proprietary Sildenafil Cream formulation available in 2025 via a 503B compounding pathway, accelerating access to treatment for women while pursuing FDA approval.
Non-Dilutive Funding and Royalty Transaction
Daré entered agreements for up to $20.7 million in non-dilutive funding and completed a $22 million royalty monetization transaction, highlighting their creative approach to funding.
Decrease in Expenses
General and administrative expenses decreased by 24% and R&D expenses by 34% in 2024 compared to 2023, reflecting effective cost management.
Ovaprene Phase III Study Progress
Enrollment for the Phase III study of Ovaprene, a non-hormonal contraceptive, has commenced with 15 active sites, reflecting ongoing advancement in their contraception portfolio.
DARE-HPV Funding
Daré received $10 million in funding to advance DARE-HPV, a treatment for HPV-related cervical diseases, towards a Phase II clinical study.
---
DARE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DARE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $2.89 | $2.90 | +0.35% |
| Nov 14, 2024 | $3.56 | $3.21 | -9.83% |
| Aug 12, 2024 | $3.50 | $4.20 | +20.00% |
| May 14, 2024 | $5.36 | $5.36 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Daré Bioscience Inc (DARE) report earnings?
Daré Bioscience Inc (DARE) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Daré Bioscience Inc (DARE) earnings time?
Daré Bioscience Inc (DARE) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DARE EPS forecast?
DARE EPS forecast for the fiscal quarter 2025 (Q1) is -0.53.
---